Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 6/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881600 | 0.92 | ROCK2 (0.46) | ROCK2CYP3A4MAP4K1MET | |
| SCHEMBL2889746 | 0.79 | ROCK2 (0.43) | ROCK2CYP3A4METNUDT1 | |
| SCHEMBL8322745 | 0.77 | ROCK2 (0.82) | ROCK2CYP3A4MET | |
| SCHEMBL2877126 | 0.76 | ROCK2 (0.54) | ROCK2CYP3A4MAP4K1METNUDT1 | |
| SCHEMBL2876385 | 0.74 | ROCK2 (0.60) | ROCK2CYP3A4MET | |
| SCHEMBL2881549 | 0.72 | ROCK2 (0.63) | ROCK2CYP3A4MET | |
| SCHEMBL22772301 | 0.71 | MAP4K1 (0.49) | ROCK2CYP3A4MAP4K1METNUDT1 | |
| SCHEMBL2881172 | 0.71 | ROCK2 (0.80) | ROCK2CYP3A4MAP4K1MET | |
| SCHEMBL13295217 | 0.71 | ROCK2 (0.80) | ROCK2CYP3A4MAP4K1MET | |
| SCHEMBL2876898 | 0.70 | ROCK2 (0.61) | ROCK2CYP3A4MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | ROCK1, ROCK2, RHOA | ROCK2 2/4885CYP3A4 2229/4885MAP4K1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.